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ABSTRACT 
Quality by design (QbD) refers to the achievement of certain predictable quality with desired and predetermined specifications. A very useful 
component of the QbD is the understanding of factors and their interaction effects by a desired set of experiments by using software (design 
expert 8). The present study describes the development of a comprehensive science and risk based HPLC method which is given by design expert 
8 and subsequent validation for the analysis of Efavirenz active pharmaceutical ingredient (API) using a quality by design approach. An efficient 
experimental design based on systematic scouting of all four key components of the RP‐HPLC method (column, pH, mobile phase and flow rate) 
is presented. The described method was linear. R2=0.9998. The precision, ruggedness and robustness values were also within the prescribed 
limits (<1% for system precision and <2% for other parameters). Chromatographic peak purity results indicated the absence of co‐eluting peaks 
with the main peak of Efavirenz. The proposed method can be used for routine analysis of Efavirenz in quality control laboratories. 
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1. INTRODUCTION 
1.1 Introduction to Drug Molecule 
Chemically efavirenz is (4S)-6-chloro-4-(2-
cyclopropylethynyl)-4-(trifluoromethyl)-2,4-dihydro-1H-
3,1-benzoxazin-2-one. It has molecular formula of 
C14H9ClF3NO2. It is crystalline powder having white or 
slightly yellowish colour. The melting point of Efavirenz is 
ranging from 136.00C to 141.00C. Efavirenz is a non-
nucleoside reverse transcriptase inhibitor (NNRTI). 
Efavirenz is directly connected to the enzyme and blocks the 
enzyme catalytic site. It is used as a part of highly active 
antiretroviral therapy for the treatment of human 
immunodeficiency virus. The drug is used in combination 
with other anti-retroviral agents for the treatment of HIV-1 
infection in children’s and adults. The usual dosage of 
efavirenz is 600mg per day. It is usually taken on empty 
stomach at bedtime to reduce neurological and psychiatric 
adverse effects. Structure of efavirenz is given in Figure no 
1.1 
1.2 Quality by Design (QbD) is a concept first outlined by 
Juran in various publications. Juran believed that quality 
could be planned and that most quality crises and problems 
relate to the way in which quality was planned in the first 
place. Experimental design (DoE), as a tool of QbD, can be 
defined as the strategy for setting up experiments in such a 
manner that the information required is obtained as 
efficiently and precisely as possible. Experimental design 
(DoE) is a powerful technique used for exploring new 
processes, gaining increased knowledge of the existing 
processes and optimizing these processes for achieving 
world-class performance. Experimentation is performed to 
determine the relationship between factors acting on the 
response. 2 
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Figure 1: Chemical structure of efavirenz 
Waghmare et al                                                                                                   Journal of Drug Delivery & Therapeutics. 2019; 9(1-s):319-330 
ISSN: 2250-1177                                                                                  [320]                                                                                 CODEN (USA): JDDTAO 
The choice of DoE is very important for the success of any 
industrial experiment. The proper selection was based on the 
process knowledge and depended on the following factors: 
 Number of factors and interactions to be studied 
 Complexity of using each design 
 Statistical validity and effectiveness of each design 
 Ease of understanding and implementation  
 Nature of the problem 
 Cost and time constraints 
The potential benefits of using a DoE rather than using 
traditional “one factor at a time” experimentation are 
summarized below: 
 Improved process yield and stability 
 Improved profits 
 Improved process capacity 
 Reduced process variability  
 Reduced manufacturing costs  
 Reduced process design and developing time.2 
1.3 Full three-level factorial designs by Design expert 8 
Software.  
Full three-level factorial design is an experimental matrix 
that has limited application in RSM when the factor number 
is higher than 2 because the number of experiments required 
for this design (calculated by expression N = 3k, where N is 
experiment number and k is factor number) is very large, 
thereby losing its efficiency in the modelling of quadratic 
functions. Because a complete three-level factorial design for 
more than two variables requires more experimental runs 
than can usually be accommodated in practice, designs that 
present a smaller number of experimental points, such as the 
Box–Behnken, central composite, and Doehlert designs, are 
more often used. However, for two variables, the efficiency is 
comparable with designs such as central composite. The 
majority of applications of three-level factorial designs are in 
the area of chromatography.2,3,4,5,6. 
2. MATERIAL AND METHODS  
2.1 Apparatus 
A UV- vis Spectrophotometer (Jasco/ v-630), was used with 
quartz cells of 10mm path length; HPLC (Jasco 12000 series); 
Column Symmetry C-18, 4.6*250mm, 5µm particle size 
(Waters); analytical balance (Contech, CB-50 series); 
ultrasonicator cleaning bath ( spectra lab / UCB-400); filter 
papers 0.45µm. 
2.2 Materials 
Efavirenz reference standard was obtained as gift sample 
from Lupin Ltd. Aurangabad, Maharashtra, India and 
formulation was procured from the market. Ammonium 
formate buffer of research grade was obtained from Fine 
chem. Industries Ltd. Mumbai. Acetonitrile of HPLC grade 
was used for research from Merck Pvt. Ltd. Mumbai. 
Stock solution of Efavirenz 1000µg/ml was prepared by 
using 10mg of Efavirenz in 10ml of methanol. 
2.3 Chromatographic System 
Analysis was carried on Symmetry C-18 4.6*250mm, 5µm 
particle size column at 292 nm. The samples were 
introduced through a Rheodyne injector valve with 20-µl 
sample loop. The mobile phase consisted of acetonitrile and 
ammonium formate (72:28, v/v), filtered through a 
membrane filter (0.45µ), degassed in ultrasonic bath, and 
pumped at a flow rate of 1.0 ml/min. 
3. RESULTS AND DISCUSSION 
3.1 Design of Experiment 
Two Columns have used 
 Column C8 
 Column C18 
3.1.1 3 level Factorial design (Miscellaneous Factorial 
design)  
Selected Factorial design was miscellaneous Factorial design 
due to it has flexibility to change/add/delete any parameter 
at any time when our experiment is going on.it provide 
facility to give standard run at one time at only one mobile 
phase.6 
3.1.2 There are selected four mobile phase  
 Acetonitrile : Water 
 Acetonitrile: Ammonium format buffer 
 Methanol : Water 
 Methanol : Ammonium format buffer.3,4,5,6 
3.1.3 Miscellaneous Factorial design can pick up one 
mobile phase. So selected each mobile phase one by one. 
 Acetonitrile : Water 
 Change pH Range: 3-5 
 Change Mobile phase proportion Range:  60-80% 
(Consider Acetonitrile) 
 Change flow rate range: 0.8-1.2 
When all above ranges put in Miscellaneous Factorial design. 
It gave 27 run at different pH, Mobile phase proportion and 
flow rate.  
Followed same procedure for each mobile phase. That is for 
column C-8 has four mobile Phase and column C-18 has four 
mobile Phases with 27 run for each mobile phase. Each 
column has its 108 run. After completion of all trails 
software give one optimize best value for each column. 
Optimization means finding an alternative with the most cost 
effective or highest achievable performance under the given 
constraints, by maximizing desired factors and minimizing 
undesired ones. In comparison, maximization means trying 
to attain the highest or maximum result or outcome without 
regard to cost or expense.  
Miscellaneous factor design was utilised for method 
development in order to evaluate the effects of amount of 
buffer, buffer pH and flow rate on responses. Total 27 runs 
were suggested by the software. Factors and responses 
considered for study were shown in table 1. Ranges 
considered were based upon previous univariate 
chromatographic separation studies. For amount of organic 
range was 60 to 80 % v/v, for pH of buffer 3 to 5 and for flow 
rate 0.8 to 1.2 mL min-1.7,8. 
3.2 Optimization 
3.2.1 Screening design for suitable chromatographic 
condition: 
Determination of suitable column and solvent system based 
on peak parameters. Methanol: water/ methanol: buffer 
(Amonium formate)/ ACN: water and ACN: buffer, these four 
mobile phases were selected for screening study on C8 and 
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C18 columns at pH 3.0, 4.0 and 5.0. These mobile phases 
were screened by varying the organic phase composition 
from 60 to 80 % v/v and flow rate from 0.8 to 1.2 mL/ min 
flow rate consider to be standard 1 ml/min because result 
are not satisfactory with 0.8 and 1.2 ml/min.  
3.2.2 Results of various trials, having organic phase 
composition 60 % v/v are shown in following tables.
 
Table 1: Trials performed on C8 column at mobile phase (60:40 v/v) with aqueous phase pH 3 
Sr.no. Composition Observation Remarks 
1 
Methanol: buffer 
(60:40 v/v) 
No peak appearance Not satisfactory 
2 
Methanol: water 
(60:40 v/v) 
No peak appearance Not satisfactory 
3 
ACN: buffer 
(60:40 v/v) 
Greater peak asymmetry and lower 
theoretical plates 
Not satisfactory 
4 
ACN: water 
(60:40 v/v) 
Greater peak asymmetry and lower 
theoretical plates 
Not satisfactory 
 
Table 2: Trials performed on C18 column at mobile phase (60:40 v/v) with aqueous phase pH 3 
Sr. no. Composition Observation Remarks 
1 
Methanol: buffer 
(60:40 v/v) 
Greater peak Asymmetry and lower 
theoretical plates 
Not satisfactory 
2 
Methanol: water 
(60:40 v/v) 
No peak appearance Not satisfactory 
3 
ACN: buffer 
(60:40 v/v) 
Less peak asymmetry but less 
theoretical plates  
Not satisfactory 
4 
ACN: water 
(60:40 v/v)  
Less peak asymmetry with more 
theoretical plates 
Satisfactory 
 
Table 3: Trials performed on C8 column at mobile phase (60:40 v/v) with aqueous phase pH 4 
Sr.no. Composition Observation Remarks 
1 
Methanol: buffer  
(60:40 v/v) 
No peak appearance Not satisfactory 
2 
Methanol: water  
(60:40 v/v) 
No peak appearance  Not satisfactory 
3 
ACN: buffer  
(60:40 v/v) 
More retention time Not satisfactory 
4 
ACN: water  
(60:40 v/v)  
More retention time  Not satisfactory 
 
Table 4: Trials performed on C18 column at mobile phase (60:40 v/v) with aqueous phase pH 4 
Sr.no. Composition Observation Remarks 
1 
Methanol: buffer  
(60:40 v/v) 
No peak appearance Not satisfactory 
2 
Methanol: water 
(60:40 v/v) 
No peak appearance Not satisfactory 
3 
ACN: buffer 
(60:40 v/v) 
Good peak properties Satisfactory 
4 
ACN: water 
(60:40 v/v) 
More retention time  Not satisfactory 
 
Table 5: Trials performed on C8 column at mobile phase (60:40 v/v) with aqueous phase pH 5 
Sr. no. Composition Observation Remarks 
1 
Methanol: buffer 
(60:40 v/v) 
No peak observed Not satisfactory 
2 
Methanol: water 
(60:40 v/v) 
No peak appearance Not satisfactory 
3 
ACN: buffer 
(60:40 v/v) 
Greater peak asymmetry with less 
theoretical plates 
Not satisfactory 
4 
ACN: water 
(60:40 v/v) 
More retention time Not satisfactory 
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Table 6: Trials performed on C18 column at mobile phase (60:40 v/v) with aqueous phase pH 5 
Sr. no. Composition Observation Remarks 
1 
Methanol: 
buffer(60:40 v/v)  
No peak observed Not satisfactory 
2 
Methanol: water 
(60:40 v/v)  
No peak observed  Not satisfactory 
3 
ACN: buffer  (60:40 
v/v)  
More retention time Not satisfactory 
4 
ACN: water 
(60:40 v/v)  
More retention time  Not satisfactory 
 
3.2.3 Results of various trials, having organic phase composition 70 % v/v are shown in following tables. 
Table 7: Trials performed on C8 column at mobile phase (70:30 v/v) with aqueous phase pH 3 
Sr. 
no. 
Composition Observation Remarks 
1 
Methanol: buffer 
(70:30 v/v) 
Greater peak asymmetry and lower 
theoretical plates  
Not satisfactory 
2 
Methanol: water 
(70:30 v/v) 
More retention time  Not satisfactory 
3 
ACN: buffer 
(70:30 v/v) 
Greater peak asymmetry and lower 
theoretical plates 
Not satisfactory 
4 
ACN: water 
(70:30 v/v)  
Greater peak asymmetry  Not satisfactory 
 
Table 8: Trials performed on C18 column at mobile phase (70:30 v/v) with aqueous phase pH 3 
Sr. 
no. 
Composition Observation Remarks 
1 
Methanol: buffer 
(70:30 v/v) 
More retention time Not satisfactory 
2 
Methanol: water 
(70:30 v/v) 
More retention time  Not satisfactory 
3 
ACN: buffer 
(70:30 v/v) 
Less peak asymmetry with more theoretical 
plates and good retention time 
More satisfactory 
4 
ACN: water  
(70:30 v/v) 
Less peak asymmetry with more theoretical 
plates and good retention time 
satisfactory 
 
Table 9: Trials performed on C8 column at mobile phase (70:30 v/v) with aqueous phase pH 4 
Sr.no. Composition Observation Remarks 
1 
Methanol: buffer  
(70:30 v/v) 
Greater peak asymmetry with lower 
theoretical plates 
Not 
satisfactory 
2 
Methanol: water  
(70:30 v/v) 
No peak appearance  
Not 
satisfactory 
3 
ACN: buffer  
(70:30 v/v) 
Less peak asymmetry with more theoretical 
plates and good retention time 
satisfactory 
4 
ACN: water  
(70:30 v/v) 
Greater peak asymmetry with more 
theoretical plates 
Not 
satisfactory 
 
Table 10: Trials performed on C18 column at mobile phase (70:30 v/v) with aqueous phase pH 4 
Sr.no. Composition Observation Remarks 
1 
Methanol: buffer  
(70:30 v/v) 
More retention time Not satisfactory 
2 
Methanol: water 
(70:30 v/v) 
More retention time Not satisfactory 
3 
ACN: buffer 
(70:30 v/v) 
Less peak asymmetry with more 
theoretical plates and good retention time 
Satisfactory 
4 
ACN: water 
(70:30 v/v) 
Less peak asymmetry with more 
theoretical plates and good retention time 
Satisfactory 
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Table 11: Trials performed on C8 column at mobile phase (70:30 v/v) with aqueous phase pH 5 
Sr. no. Composition Observation Remarks 
1 
Methanol: buffer 
(70:30 v/v) 
More retention time Not satisfactory 
2 
Methanol: water 
(70:30 v/v) 
Greater peak asymmetry  Not satisfactory 
3 
ACN: buffer 
(70:30 v/v) 
Greater peak asymmetry with less 
theoretical plates  
Not satisfactory 
4 
ACN: water 
(70:30 v/v) 
Greater peak asymmetry with less 
theoretical plates  
Not satisfactory 
 
Table 12: Trials performed on C18 column at mobile phase (70:30 v/v) with aqueous phase pH 5 
Sr. no. Composition Observation Remarks 
1 Methanol: buffer (70:30 v/v) More retention time Not satisfactory 
2 Methanol: water (70:30 v/v) More retention time Not satisfactory 
3 
ACN: buffer 
(70:30 v/v) 
Less peak asymmetry with more theoretical 
plates and good retention time 
More satisfactory 
4 
ACN: water  
(70:30 v/v)  
Less peak asymmetry with more theoretical 
plates and good retention time 
satisfactory 
 
3.2.4 Results of various trials, having organic phase composition 80 % v/v are shown in following tables. 
Table 13: Trials performed on C8 column at mobile phase (80:20 v/v) with aqueous phase pH 3 
Sr. no. Composition Observation Remarks 
1 
Methanol: buffer  
(80:20 v/v) 
Greater peak asymmetry and 
More retention time  
Not satisfactory 
2 
Methanol: water  
(80:20 v/v) 
Greater peak asymmetry  Not satisfactory 
3 
ACN: buffer 
 (80:20 v/v) 
Greater peak asymmetry Not satisfactory 
4 
ACN: water 
 (80:20 v/v) 
Greater peak asymmetry and 
lower theoretical plates  
Not satisfactory 
 
Table 14: Trials performed on C18 column at mobile phase (80:20 v/v) with aqueous phase pH 3 
Sr. no. Composition Observation Remarks 
1 Methanol: buffer (80:20 v/v)  Lower theoretical plates Not satisfactory 
2 Methanol: water (80:20 v/v) Lower theoretical plates Not satisfactory 
3 ACN: buffer (80:20 v/v) Less retention time Not satisfactory 
4 ACN: water (80:20 v/v) Lower theoretical plates satisfactory 
 
Table 15: Trials performed on C8 column at mobile phase (80:20 v/v) with aqueous phase pH 4 
Sr.no. Composition Observation Remarks 
1 
Methanol: buffer  
(80:20 v/v) 
Greater peak asymmetry and lower 
theoretical plates with more retention 
time  
Not satisfactory 
2 
Methanol: water  
(80:20 v/v) 
Greater peak asymmetry  Not satisfactory 
3 
ACN: buffer  
(80:20 v/v) 
Greater peak asymmetry and lower 
theoretical plates  
Not satisfactory 
4 
ACN: water  
(80:20 v/v) 
Greater peak asymmetry and lower 
theoretical plates  
Not satisfactory 
 
Table 16: Trials performed on C18 column at mobile phase (80:20 v/v) with aqueous phase pH 4 
Sr.no. Composition Observation Remarks 
1 
Methanol: buffer   
(80:20 v/v) 
No peak appearance Not satisfactory 
2 
Methanol: water  
(80:20 v/v) 
No peak appearance Not satisfactory 
3 
ACN: buffer  
(80:20 v/v) 
Less retention time  Satisfactory 
4 
ACN: water  
(80:20 v/v) 
Good peak properties satisfactory 
 
Waghmare et al                                                                                                   Journal of Drug Delivery & Therapeutics. 2019; 9(1-s):319-330 
ISSN: 2250-1177                                                                                  [324]                                                                                 CODEN (USA): JDDTAO 
Table 17: Trials performed on C8 column at mobile phase (80:20 v/v) with aqueous phase pH 5 
Sr. no. Composition Observation Remarks 
1 
Methanol: buffer  
(80:20 v/v) 
Greater peak asymmetry Not satisfactory 
2 
Methanol: water 
 (80:20 v/v) 
less theoretical plates Not satisfactory 
3 
ACN: buffer 
 (80:20 v/v) 
Greater peak asymmetry with less 
theoretical plates 
Not satisfactory 
4 
ACN: water  
(80:20 v/v) 
Greater peak asymmetry with less 
theoretical plates 
Not satisfactory 
 
Table 18: Trials performed on C18 column at mobile phase (80:20 v/v) with aqueous phase pH 5 
Sr. no. Composition Observation Remarks 
1 
Methanol: buffer  
(80:20 v/v) 
lower theoretical plates Not satisfactory 
2 
Methanol: water 
 (80:20 v/v) 
lower theoretical plates Not satisfactory 
3 
ACN: buffer  
(80:20 v/v) 
Good peak properties satisfactory 
4 
ACN: water  
(80:20 v/v) 
Lower retention time Not satisfactory 
 
3.3 Optimized trials suggested by software based on 
desirability value 
This methodology is initially based on constructing a 
desirability function for each individual response. The scale 
of individual desirability function ranges between i= 0, for 
completely undesirable response and i =1, for fully desired 
response. Selection of trial was based on maximum 
desirability value. Therefore, first trial which was having 
desirability one (i=1) selected for method optimization.8, 9,10. 
 
Table 19: Optimized trials suggested by software based on desirability value 
Sr. no. 
Amount 
of CAN 
pH of 
buffer 
Flow 
rate 
Retention 
time 
Tailing 
factor 
Theoretical 
plates 
Desirability 
1 72.03 5.0 1.0 5.6 0.96 9084.48 1.0 
2 72.00 5.0 1.0 5.9 1.01 9124.84 0.9 
3 72.56 5.0 1.1 5.7 1.03 9025.81 1.0 
4 70.02 5.0 1.0 5.76 0.99 8997.3 0.96 
 
 
3.3.1 Optimized chromatographic conditions 
Mobile phase: Ammonium format buffer: ACN (28:72 v/v), pH 
of buffer: 5, Analytical column: C18 column Waters XBridge 
(4.6× 250mm id. particle size 5µm), UV detection: 247 nm, 
Injection volume: 20 µL, Flow rate: 1.00 mL min -1, 
Temperature: Ambient, Run time: 10 min  
3.4 Effect of independent variables 
3.4.1 Effect of independent variables on retention time 
(Y1): 
The equation for response surface quadratic model is as 
follows 
Y1 =  +5.56 -2.58 X1+ 0.50X2 –1.52 X3 + 0.14 X1X2 +0.79X1X3+ -
0.099 X2X3 + 1.45X12  + 0.46X22  + 0.96 X32                                                                                   
(1) 
Where, X1=  A, X2 = B and X3= C 
a graphical representation of amount of ACN (A) and ﬂow 
rate (C), while  pH of buffer (B) is maintained constant at its 
optimum of 5. An increase in ﬂow rate resulted in decrease 
in retention time (Y1), while increase in % v/v of buffer (or 
amount of buffer) resulted in increase in retention time (Y1). 
Combination of amount of buffer and flow rate showed 
decrease in response. 
 
Figure 2(a): Three-dimensional plot for retention time 
as a function of flow rate and amount of ACN. Constant 
factor (pH of buffer- 5.0) 
Fig.3 (b) shows a graphical representation of pH of buffer (B) 
and amount of buffer (A), while flow rate (C) is maintained 
constant at its optimum of 1 mL min-1.  Increase in pH of 
buffer showed increase in retention time (Y1), also increase 
in amount of buffer showed synergistic effect on Y1. 
Combination of amount of buffer and pH of buffer showed 
antagonistic effect on response.  
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Figure 3(b): Three-dimensional plot for retention time 
as a function of pH of buffer and amount of buffer. 
Constant factor (flow rate- 1mL min-1) 
Fig.4.(c) shows a graphical representation of pH of buffer (B) 
and flow rate (C), while amount of buffer (A) is maintained 
constant at its optimum of 40 % v/v. An increase in flow rate 
showed antagonistic effect on response (Y1), while increase 
in pH of buffer showed synergistic effect on the response. pH 
of buffer and flow rate combination found for having 
synergistic effect on response.  
 
Figure 4(c): Three-dimensional plot for retention time 
as a function of flow rate and  pH of buffer. Constant 
factor (% v/v of buffer- 40) 
Fit summary: Quadratic model was suggested by the 
software. 
ANOVA: ANOVA of developed Full three level factorial 
model for retention time (Y1). 
Values of "Prob > F" (p- value) less than 0.0500 indicate 
model terms are significant.   
In this case A, B, BC, A2 and C2 are significant model terms.
  
Table 20: Significance of p value on model terms of retention time 
Model terms p value Effect of factor Remarks 
A (X1) 0.0001 -2.58 Significant 
B (X2) 0.0115  +0.50 Significant 
C (X3)  0.0001 -1.52 Significant 
AB (X1X2) 0.5381  +0.14  Insignificant 
AC (X1X3) 0.0021 +0.79 Significant 
BC (X2X3) 0.6555 -0.099 Insignificant 
A2 (X21) 0.0002 +1.45 Significant 
B2 (X22) 0.1565 +0.46 Insignificant 
C2 (X23) 0.0061 +0.96 Significant 
Overall model 0.0029 - Significant 
 
3.4.2 Effect of independent variables on tailing factor 
(Y2): 
After applying experimental design, suggested Response 
Surface Linear Model was found to be significant with 
model F value of 23.79, p value less than 0.005 and R2 value 
of 0.7563. There is only a 0.01% chance that a "Model F-
Value" this large could occur due to noise. Values of % C.V. 
and adjusted R2 were 3.78 and 0.7245 respectively. The 
model for response Y2 (tailing factor) is as follows: 
Y2 =   +0.98 +0.071X1-0.021X2+3.333 E-003X3 
 
Figure 5(a): Three-dimentional plot for tailing factor as 
a function of flow rate and amount of buffer. Constant 
factor (pH of buffer- 5) 
Fig.6.(b) shows a graphical representation of pH of buffer 
(B) and amount of buffer (A), while flow rate (C) is 
maintained constant at its optimum of 1.0 mL min-1. An 
increase in pH of buffer had antagonistic effect on response 
(Y2) while increase in amount of ACN showed synergistic 
effect on it. Amount and pH of buffer combination showed 
antagonistic effect on response.  
 
Figure 6(b): Three-dimentional plot for tailing factor as 
a function of pH of buffer and  % v/v of buffer. Constant 
factor (flow rate- 1mL min-1) 
Fig.7.(c) shows a graphical representation of pH of buffer 
(B) and flow rate (C), while amount of buffer (A) is 
maintained constant at its optimum 40 % v/v. An increase 
in pH of buffer and flow rate showed antagonistic effect on 
response (Y2). Combination of flow rate and pH of buffer 
showed synergistic effect.  
 
Figure 7(c): Three-dimentional plot for tailing factor as 
a function of flow rate and pH of buffer. Constant factor 
(amount of buffer) 
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Fit summary: Response Surface Linear Model was 
suggested by the software. 
ANOVA: ANOVA of developed CCD model for tailing 
factor (Y2). 
Values of "Prob > F" (p- value) less than 0.0500 indicate 
model terms are significant.   
In this case A, B are significant model terms.
    
Table 21: Significance of p value on model terms of tailing factor 
Model terms p value Effect of factor  Remarks 
A (X1) 0.090 +0.071 Significant 
B (X2) 0.0271 -0.021 Significant 
C (X3) 0.7054 +3.333 Insignificant 
Overall model 0.044  - Significant 
 
For response Y2, factor X1 and X3 was having synergistic 
effect with p value 0.090 and 0.7054. Therefore  we can 
conclude that increment in amount of ACN and flow rate  
was responsible for decrease in tailing factor and thus 
showed the direct relationship between them. Terms X2 
were responsible for significant increase in tailing factor 
with p values -0.0271. Therefore we can conclude that 
combination of factors showed inverse relationship with 
response. Factors amount of ACN and combination of flow 
rate and amount of buffer differs from zero with a great 
margin therefore they were having more significant effect 
than other factors.  
3.4.3 Effect of independent variables on theoretical 
plates (Y3): 
After applying experimental design, suggested Response 
Surface Quadratic Model was found to be significant with 
model F value of 4.38, p value less than 0.005 and R2 value 
of 0.6988. There is only a 0.43% chance that a "Model F-
Value" this large could occur due to noise. Values of % C.V. 
and adjusted R2 were 18.43 and 0.5394 respectively. The 
model for response Y3 (theoretical plates) is as follows: 
Y3 = +6409.99 -1700.54X1 +283.43X2 -322.85X3 -602.20X1X2 + 
445.98X1X3 -323.61X2X3 +243.15 X21 +510.74X22   +2176.65X23       
(3) 
Fig.8 .(a) shows a graphical representation of amount of 
ACN (A) and  flow rate (C), while pH of buffer (B) is varying 
from 3-5. 
An increase in flow rate and amount of ACN showed 
antagonistic effect on response (Y3) individually, while 
their combination showed synergistic effect on response. 
1,10. 
 
Figure 8(a): Three-dimensional plot for theoretical 
plates as a function of flow rate and amount of ACN. 
Constant factor pH-5 
Fig.9.(b) shows a graphical representation of amount of 
ACN (A) and  pH of buffer (B), while flow rate (C) is 
maintained constant at its optimum value 1mL min-1. An 
increase in pH of buffer showed increase in number of 
theoretical plates (Y3), while increase in amount of ACN 
showed antagonistic effect on response. Combination of 
amount of buffer and pH of buffer showed antagonistic 
effect on it.  
 
Figure 9(b): Three-dimensional plot for theoretical 
plates as a function of pH of buffer  and  % v/v of buffer. 
Constant factor (flow rate- 1 mL min-1) 
Fig.10.(c) shows a graphical representation of flow rate (C) 
and  pH of buffer (B), while amount of ACN (A) is 
maintained constant at its optimum value 70 % v/v. An 
increase in pH of buffer showed increase in number of 
theoretical plates (Y3), while, increase in flow rate showed 
antagonistic effect on response. Combination of flow rate 
and pH of buffer showed antagonistic effect on response. 
 
Figure 10(c): Three-dimensional plot for theoretical 
plates as a function of pH of buffer and flow rate. 
Constant factor (amount of buffer) 
Fit summary: Quadratic model was suggested by the 
software 
ANOVA: ANOVA of developed CCD model for theoretical 
plates (Y3). 
Values of "Prob > F" (p- value) less than 0.0500 indicate 
model terms are significant.  In this case B, AC, B2 and C2 
are significant model terms. 
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Table 22: Significance of p value on model terms of theoretical plates 
Model terms p value Effect of factor Remarks 
A (X1) 0.0043 -388.5 Significant 
B (X2) 0.4460 +240.4 Insignificant  
C (X3) 0.3866 -211 Insignificant 
AB (X1X2) 0.1936 -419.2 Insignificant 
AC (X1X3) 0.3302 +0.50 Insignificant 
BC (X2X3) 0.4769 -78.1 Insignificant 
A2 (X21) 0.7040 -210.2 Insignificant 
B2 (X22) 0.4282 +387.2 Insignificant 
C2 (X23) 0.0030 +73.2 Significant 
Overall model 0.0134 - Significant 
 
For response Y3, factor pH of buffer was having synergistic 
effect with p value 0.4460. Therefore we can conclude that 
increment in pH of buffer was responsible for increment in 
theoretical plates and thus showed the direct relationship 
between them. 
Combination of amount of ACN and flow rate was 
responsible for significant increase in theoretical plates with 
significant p value of 0.0043. Therefore direct relationship 
between this combination and response is observed. 
Exponential terms (X22) and (X23) also showed direct 
relationship with response having significant p values 
0.4282 and 0.0030 respectively. Factor pH of buffer and its 
exponential term differs from zero with a great margin 
therefore they were having more significant effect than other 
factors. Therefore it is concluded that pH of buffer and its 
exponential term was responsible for significant change in 
response i.e. nos. of theoretical plates. 10, 11,12,13,14. 
3.5 Analytical Method Development  
Different mobile phases were investigated to develop the 
suitable HPLC method for the analysis of Efavirenz in 
formulations. For the selection of media the criteria 
employed was sensitivity of the method, ease of sample 
preparation, miscibility of the drug, cost of solvents and 
applicability of method to various purposes. Retention time 
and peak area of EFV in the selected medium at respective 
wavelengths were determined and compared with the 
reference standards and formulation also.9,10 
    Chromatogram of Efavirenz  
 
Figure 11: A typical chromatogram of Efavirenz 
The applied chromatographic conditions permitted a good 
separation of Efavirenz in a short retention time of 5.642min. 
(Fig.11), no drug decomposition was observed during the 
analysis. The LC method was validated for the parameters 
reported below. 
3.6 System suitability study 
According to USP, system suitability tests are integral part of 
liquid chromatographic methods. Retention time, peak area 
and number of theoretical plates were calculated for 
standard solutions. The obtained data was found to be within 
acceptable limits. 
Table 23: System suitability parameters 
Sr. No. Parameters Observation 
1 Retention time 5.6 
2 Peak area 764985.5 
3 Theoretical plates 8182.42 
 
3.7 Analytical Validation  
3.7.1 Preparation of Calibration Curve  
Stock solution was prepared using 10mg of Efavirenz in 
10ml of methanol and further dilutions were done with 
mobile phase. Solutions were sonicated for 5 min in 
Ultrasonic clean bath and manually 20µl was injected 
through the Rheodyne injector. Five concentrations were 
taken 5-25µg/ml for the calibration curve at 292nm. 
Linearity graph for Efavirenz is shown in Figure no 12 and 
Overly spectra of Efavirenz Linearity shown in figure no 13.6 
 
Figure 12: Linearity graph for Efavirenz 
 
Figure 13: Overly spectra of Efavirenz Linearity 
3.7.2 Selectivity 
10 tab of EFV formulation were triturated in mortar pestle 
and 35mg (10 mg of pure drug) of tab including other 
excipients was transferred in 10 ml volumetric flask and 
volume was adjusted with methanol. Peak area and retention 
time of formulation was compared with the API of the drug. 
Typical peak of Efavirenz is shown in figure no 14.7 
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.     
Figure 14: A typical chromatogram of Efavirenz 
[Concentration 15ug/ml] 
3.7.3 Sensitivity 
The sensitivity of measurement of EFV by use of the 
proposed method was estimated in terms of the limit of 
detection (LOD) and the limit of quantification (LOQ). The 
LOD and LOQ were calculated by the use of signal to noise 
ratio. In order to estimate the LOD and LOQ values, the 
blank sample was injected six times and the peak area of 
this blank was calculated as noise level. The LOD was 
calculated as three times the noise level, while ten times the 
noise value gave the LOQ. LOD and LOQ were found to be 
0.126 and 0.420.9 
3.7.4 Accuracy 
Accuracy of analytical procedure expresses the closeness 
of agreement between the value which is accepted either 
as a conventional true value or an accepted reference value 
and the value found. This is sometimes termed trueness. 
Accuracy should be established across the specified range of 
98-102 %. 
For accuracy three concentrations of five replicates were 
prepared and injected to get the peak area. Results obtained 
are shown in table 101.11 
 
Table 24: Accuracy results of EFV by RP-HPLC 
Concentration 
(ug/ml) 
Peak area 
Concentration Found 
(µg/ml) 
Accuracy 
7 276510 7.034880 100.498296 
17 671362.4 17.25204161 101.4825 
22 854793 21.99847332 99.9930 
 
3.7.5 Precision 
The precision of an analytical procedure expresses the 
closeness of agreement (degree of scatter) between the 
series of measurements obtained from multiple sampling of 
the same homogeneous sample under the prescribed 
conditions. Method of precision was accessed on two levels, 
intra and intermediate precision. Solutions of known 
concentration were prepared in replicates and were injected 
to get the peak area. Results obtained are shown in table 99. 
12
 
Table 25: System Precision results for EFV by RP-HPLC 
Sr. No. 
 
Concentration (µg/ml) 
 
Intraday precision (Area) 
 
Interday precision (Area) 
 
1 
 
20 1504212 
 
 
1512836 
 2 
 
20 1504696 
 
1516408 
 3 
 
20 1525934 
 
1538275 
 4 
 
20 1499974 
 
1502956 
 5 
 
20 1506282 
 
1519144 
 6 
 
20 1485784 
 
1495784 
 Mean 
 
 1504480.333 
 
1514233.833 
 Std. Dev. 
 
 12911.11344 
 
14672.11126 
 %RSD 
 
 0.858177615 
 
0.968946205 
  
3.7.6 Specificity 
Chromatogram of EFV showed peak at a retention time 
of 5.018 min. The mobile phase designed for the method 
resolved the drug very efficiently; The Retention time of 
Efavirenz was 5.020 ± 0.0078min. The wavelength 292 
nm was selected for detection because; it resulted in 
better detection sensitivity for the drug. The peak for 
Efavirenz from the tablet formulations was identified by 
comparing its retention time and Area of peak with those of 
standard Efavirenz. Recovery was found to be 99.28 ± 0.004. 
The result was shown in table 107.13 
 
Table 26: Recovery results of EFV by RP-HPLC 
Sample Label Claim mg Amount found* (mg) Recovery ± SD* (%) Retention time 
Tab 600 599.96 99.28 ± 0.004 5.6 ± 0.0078 min 
 
3.7.7 Repeatability 
Demonstration of precision was done under two categories. 
The injection repeatability (System Precision) was assessed 
by using six injections of the standard solution o f EFV 
and the % RSD of the replicate injections was 
calculated. Results obtained are shown in table 100.14 
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Table 27: Repeatability results for EFV by RP-HPLC 
Sr. no 
Concentration 
µg/ml 
Peak Area 
1 20 1490913 
2 20 1497975 
3 20 1499391 
4 20 1516768 
5 20 1499974 
6 20 1516768 
Mean  1503631.5 
Std. Dev  10679.4255 
% RSD  0.710242204 
 
3.7.8 Robustness 
Robustness is a measure of capacity of a method to remain 
unaffected by small, but deliberate variations in the 
method conditions, and is indications of the reliability of 
the method. A method is robust, if it is unaffected by 
small changes in operating conditions. To determine the 
robustness of this method, the experimental conditions 
were deliberately altered at three different levels 
and retention time and chromatographic response 
were evaluated. One factor at a time was changed to study 
the effect. Variation of mobile phase composition ( 72:28 
v/v),  flow rate by 1 ml/min (0.9 and 1.1 ml/min), 
Variation of wavelength by 247 nm (245nm and 247nm), 
Variations in pH by 5 (4.8 and 5.2) had no significant effect 
on the retention time and chromatographic response of 10 
μg/ml solution, indicating that the method was robust, The 
result was shown in table 102, 103,104 and 105.6,7. 
Mobile Phase  
Table 28: Results of Robustness (Mobile Phase) for EFV 
by RP-HPLC 
Buffer Acetonitrile Retention time 
30 70 5.9 
28 72 5.6 
26 74 5.3 
 %RSD 1.8 
 
Wavelength 
Table 29: Results of Robustness (Wavelength) for EFV by 
RP-HPLC 
Wavelength Peak area 
245 742144.500 
247 735436.709 
249 724684.750 
%RSD 1.2 
 
Flow rate 
Table 30: Results of Robustness (Flow rate) for EFV by 
RP-HPLC 
Flow rate Retention time 
0.9 ml/min 6.1 
1 ml/min 5.6 
1.1 ml/min 5.1 
%RSD 1.7 
 
pH of mobile phase  
Table 31: Results of Robustness (pH) for EFV by RP-HPLC 
Sr. No  pH Peak area 
1 4.8    742144.500 
2 5 765436.709 
3 5.2 784684.750 
 %RSD 1.2 
 
3.7.9 Recovery 
The recovery of the method was determined by use of 
standard additions at three different levels, i.e. multiple-
level recovery studies. Preanalysed samples of EFV were 
spiked with extra 80, 100 and 120 % of the standard 
EFV and the mixtures were reanalysed by the proposed 
method and the % recovery was determined. Values were 
found to be within the limits and are presented in table 106. 
2,3.
 
Table 32: Recovery results of EFV by RP-HPLC 
Sr. No 
Amount of 
sample 
(µg/ml) 
Amount of drug 
added (µg/ml) 
 
Amount 
Recovered* 
(µg/ml) 
 
% Recovery ± 
SD* 
1 10 
 
8 
 
7.96 
 
98.88 ± 0.31 
 2 10 
 
 
10 
 
9.88 
 
99.01 ± 0.58 
 3 10 
 
12 
 
11.72 
 
98.46 ± 0.41 
  
4. SUMMARY AND CONCLUSION  
7.1  Determination of Efavirenz by HPLC.  
In this project, as per our objective RP-HPLC method was 
developed by implementing QbD methodology (RSM and 3 
level factorial design) on analytical column- reversed phase 
Waters XBridge C18 (250mm×4.6mm×5μm) with mobile 
phase Amonium format: Acetonitrile (28:72 v/v). The flow 
rate used was 1 mL /min and UV detection was carried out at 
247 nm. The retention time for Efavirenz was found to be 5.6 
min. Before method optimization, screening studies were 
carried out on different mobile phases, varying composition 
and pH. Based on the results obtained from these studies, 
suitable mobile phase with appropriate composition and pH 
was selected and utilized for method development using QbD 
methodology.  
The RP-HPLC method developed for estimation of Efavirenz 
was validated as per ICH guidelines using various 
parameters.  
Linearity for the drug by the proposed method was 
determined to study its ability to elicit test results which are 
directly proportional to the concentration of analyte in the 
sample response and was found to be in concentration range 
5 to 25 μg/mL (R2 = 0.998).  
The limit of detection (LOD) and limit of quantitation (LOQ) 
was established at a signal-to-noise ratio. LOD and LOQ were 
calculated as 3.3×δ/S and 10×δ/S respectively as per ICH 
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guidelines, where δ is the standard deviation of the response 
(y-intercept) and S is the slope of the calibration plot. LOD 
was found to be 0.126μg/ mL and LOQ was found to 0.420 
μg/ mL  
System suitability test ensures that the analytical system is 
working properly and can give accurate and precise results. 
System suitability tests includes resolution, tailing factor, 
number of theoretical plates, capacity factor etc. The results 
of all system suitability parameters were acceptable in their 
limits defined by official guidelines.  
The proposed high-performance liquid chromatographic 
method has also been evaluated over the accuracy, precision 
and robustness and proved to be convenient and effective for 
the quality control of Efavirenz. Developed method was 
found simple and cost effective for the quality control of 
Efavirenz.  
Moreover, the lower solvent consumption along with the 
short analytical run time of 10.0 min leads to a cost effective 
and environmentally friendly chromatographic procedure. 
Thus, the proposed methodology is rapid, selective, requires 
a simple sample preparation procedure, and represents a 
good procedure for Efavirenz. 
Table 33: Results of the quantitative determination of 
Efavirenz. 
Sr. 
no 
Parameters HPLC observations 
1 Concentration range (μg mL-1) 5-25 
2 Regression equation y = 73923x + 4930.6 
3 Correlation coefficient 0.998 
4 LOD (μg mL-1) 0.126 
5 LOQ (μg mL-1) 0.420 
 
5. FUTURE SCOPE  
QbD methodology can be applied for Bioanalytical method 
development and its validation for estimation of EFV.  
QbD methodology can be applied for stability indicating 
studies of EFV.  
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